Chemical Library


The Institute Curie/CNRS Chemical Library was created from the chemical molecules synthesized by the chemists of the Institute Curie of Paris (UMR3666 / U1143) and Orsay (UMR9187 / U1196). This academic chemical library, one of the most important of France, contains almost 10000 substances. Such a set of chemicals is constituted not only of the final products, but also of synthetic intermediates obtained during the programs of optimization against various therapeutic targets.
Since its creation, 65 years ago, the main motivation of the chemistry laboratory of the Institute Curie has been the discovery of molecules for cancer treatment. A direct consequence of this activity is the existence (often in significant quantities) of samples of several thousands of synthesized compounds. Moreover, advances in proteomics and genomics have led to the discovery of an increasing number of new protein targets with therapeutic potential.

By screening small molecules, either individually or, preferably, as collections called libraries of small molecules (chemical libraries), many opportunities are offered to discover or identify biologically active molecules, which are tools in “Chemical Biology” or “drugs of tomorrow”. In parallel the approach of rational conception, the serendipity is at the origin of the identification of many active ingredients. So, in coupling chemical libraries and platforms of screening, it is possible “to accelerate the fate”. In this context, the chemical libraries of diverse institutes and French universities federated to form the National Chemical library (CN), this federation is supported by the CNRS (GIS-Chimiothèque nationale). This movement begun in 2001 was at the origin of the creation of the Chemical library of the institute Curie.

The compounds of the chemical library are available on 96 or 384 wells microplates directly usable for diverse tests. The Chemical library continues to grow by addition of the new molecules synthesized by the chemists.


As platform, the biologists in particular those of the Institute Curie and the customers of the National Chemical library can access to these molecules for selected assays by contract as part of a discovery partnership. The miniaturization and the automation of the biological tests allow screening the set or the part of the Chemical library to discover “Hits”. The screenings can serve to select compounds which can interfere with biological phenomena. The results of these tests then give rise to scientific productions (publication and\or patent).

An expertise in chemical optimization of “Hit” (synthesis of structural analogues to establish for example a relation Structure / activity) is also proposed to the partner biologists by the platform Chemical library to understand better the involved biological phenomena or to improve the activity in a therapeutic purpose. The development of molecular tools to identify the biological targets of “hit” can be also envisaged at the end of the assays of chemical optimization. The screening of the chemical library thus leads to scientific collaborations between biologists and chemists.



 Screening platforms

Biophenics “Plateforme de criblage cellulaire à haut débit”  – Institut Curie – Paris – Elaine DEL NERY SANTOS –
PCBIS «  Plate-forme de Chimie Biologique Intégrative de Strasbourg » – Pascal VILLA –
« Plate-forme de Criblage pour des molécules BioActives » – CEA Grenoble – Caroline BARETTE –
PICT « Plateforme Intégrée de Criblage de Toulouse » – Frédéric AUSSEIL –
CBC « Criblage Biologique et Chimiothèque » – Institut Pasteur – Paris – Hélène LEHMANN-MUNIER –

Drug Technologies platform

TechMedIll – Strasbourg- Patrick GIZZY-

Collaboration inside Curie

Johannes Ludger – Chemical Biology of membranes and therapeutic delivery, UMR3666/U1143,

Mounira Amor-Guéret – UMR 3348 – Stress génotoxiques et cancer

Yves Pommier – Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, USA –


  • The collection can be supplied in its entirety or partially by contract as part of a discovery partnership. Samples are available under various formats: powder or in solution in the DMSO (in plate 96 wells or 384 wells, 10 mM).
  • A help to the selection of samples is also proposed by molecular modeling and virtual screening: research by similarity, sub-structure, fragments, classification by family… Other sharper methods (docking, QSAR, pharmacophore) can be also proposed.
  • An expertise in chemistry “hit-to-lead” is also possible. Resynthesis of active products or hits, synthesis of structural analogues can be realized by the chemists of units or by the platform chemical library. To assure this service, the platform is equipped by a robot of synthesis, an automated microwave, and automatic purifiers.
  • Tools of molecular chemistry to identify the biological target can be developed on request by the platform.
  • Collaborations with platforms of academic screening or drug discovery can be proposed


  • Nouveau robot en cours d’achat
  • Microwave CEM
  • Synthesis robot Chemspeed
  • LC-MS Waters
  • Combi Flash Companion/ Puriflash Interchim


Key publications

Year of publication 2020

Küssau T., Van Wyk N., Johansen M.D., Alsarraf H.M.A.B., Neyret A., Hamela C., Sørensen K.K., Thygesen M.B., Beauvineau C., Kremer L., Blaise M. (2020 Nov 4)

Functional Characterization of the N-Acetylmuramyl-l-Alanine Amidase, Ami1, from Mycobacterium abscessus

Cells : 9 : 2410 : DOI : 10.3390/cells9112410

Year of publication 2019

El Hassen Mokrani, Abderrahmane Bensegueni, Ludovic Chaput, Claire Beauvineau, Hanane Djeghim, Liliane Mouawad (2019 May 1)

Identification of New Potent Acetylcholinesterase Inhibitors Using Virtual Screening and In Vitro Approaches.

Molecular informatics : 38 : 1800118 : DOI : 10.1002/minf.201800118
Pauline Gilson, Morgane Couvet, Laetitia Vanwonterghem, Maxime Henry, Julien Vollaire, Vladimir Baulin, Marco Werner, Anna Orlowska, Véronique Josserand, Florence Mahuteau-Betzer, Laurence Lafanechère, Jean-Luc Coll, Benoit Busser, Amandine Hurbin (2019 Feb 1)

The pyrrolopyrimidine colchicine-binding site agent PP-13 reduces the metastatic dissemination of invasive cancer cells in vitro and in vivo.

Biochemical pharmacology : 160 : 1-13 : DOI : S0006-2952(18)30503-3

Year of publication 2017

Pauline Gilson, Fernando Josa-Prado, Claire Beauvineau, Delphine Naud-Martin, Laetitia Vanwonterghem, Florence Mahuteau-Betzer, Alexis Moreno, Pierre Falson, Laurence Lafanechère, Véronique Frachet, Jean-Luc Coll, Jose Fernando Díaz, Amandine Hurbin, Benoit Busser (2017 Sep 2)

Identification of pyrrolopyrimidine derivative PP-13 as a novel microtubule-destabilizing agent with promising anticancer properties.

Scientific reports : 7 : 10209 : DOI : 10.1038/s41598-017-09491-9
Buchieri Maria V., Cimino Mena , Rebollo-Ramirez Sonia, Beauvineau Claire, Cascioferro Alessandro, Favre-Rochex Sandrine, Helynck Olivier, Naud-Martin Delphine, Larrouy-Maumus Gerald, Munier-Lehmann Hélène, Gicquel Brigitte (2017 Aug 28)

Nitazoxanide Analogs Require Nitroreduction for Antimicrobial Activity in Mycobacterium smegmatis

Journal of Medicinal Chemistry : 60 : 7425-7433 : DOI : 10.1021/acs.jmedchem.7b00726
Marianne Lucas-Hourani, Daniel Dauzonne, Hélène Munier-Lehmann, Samira Khiar, Sébastien Nisole, Julien Dairou, Olivier Helynck, Philippe V Afonso, Frédéric Tangy, Pierre-Olivier Vidalain (2017 Aug 16)

Original Chemical Series of Pyrimidine Biosynthesis Inhibitors That Boost the Antiviral Interferon Response.

Antimicrobial agents and chemotherapy : 61 : e00383-17 : DOI : 10.1128/AAC.00383-17
All publications